Groundbreaking Results of Heart Failure Treatment to be Unveiled at Heart Failure 2026
The upcoming Heart Failure 2026 congress, hosted by the Heart Failure Association of the European Society of Cardiology, is set to witness a pivotal presentation centered on innovative therapies for heart failure. On May 9, 2026, Dr. Ross T. Campbell from the University of Glasgow will introduce the results of the SUBCUT HF II trial, which focuses on the effectiveness of at-home subcutaneous diuretic therapy using Lasix® ONYU. This groundbreaking study addresses a pressing issue in heart failure management by comparing at-home treatment with conventional inpatient intravenous diuretic therapy.
Heart failure is a debilitating condition affecting millions worldwide, particularly those over the age of 65. One of the major complications faced by these patients is edema, which can lead to frequent hospitalizations and requires hospitalization for intravenous diuretics.
The SUBCUT HF II trial, a randomized controlled trial, involved 170 patients across 20 National Health Service (NHS) hospitals in the U.K. Patients were randomly assigned to either continue their inpatient treatment with intravenous furosemide or to self-administer subcutaneous furosemide using the Lasix ONYU Infusor at home. This innovative device delivers furosemide in a controlled manner, allowing patients to manage their condition more independently while avoiding the confines of hospital stays.
The primary outcome measured by this trial is the total number of days patients spent alive and out of the hospital over a 30-day period, a crucial metric that underscores the importance of treatment efficacy and quality of life for heart failure patients.
SQ Innovation's Lasix® ONYU is unique in that it combines a high-concentration formulation of furosemide delivered through a specialized device designed for subcutaneous administration. The FDA approved this novel drug-device combination in October 2025, recognizing its potential to alleviate the burden of hospital-based care for heart failure patients.
The presentation at Heart Failure 2026 will not only share the trial results but also highlight the potential impacts on patient treatment paradigms; if successful, this could shift many cases of heart failure outpatient management significantly. Following the main presentation, Jan Biegus from the Institute of Heart Diseases will discuss the implications of the findings, providing further context to the scientific community.
This major trial was co-sponsored by the University of Glasgow and the Greater Glasgow and Clyde Health Board, with backing from SQ Innovation. The study’s approach recognizes the pressing need for techniques that allow patients to receive effective treatment within their homes while minimizing healthcare resource utilization. The results may pave the way for future studies and larger trials to solidify subcutaneous diuretic therapy as a valid standard of care in managing edema associated with chronic heart failure.
As heart failure rates continue to rise globally, innovations like Lasix ONYU represent a significant step toward enhancing patient autonomy and improving overall health outcomes. The SUBCUT HF II trial serves as a beacon of hope for those grappling with the challenges of heart failure, illuminating a path toward more effective and less disruptive treatment alternatives.
With this upcoming landmark presentation at Heart Failure 2026, SQ Innovation stands at the forefront of a potential paradigm shift in heart failure treatment. The healthcare community will be eager to see whether the findings substantiate the efficacy of at-home subcutaneous therapy as a viable solution for patients requiring long-term diuretic treatment, marking an important milestone in the journey of cardiac care innovation.
Heart failure is a debilitating condition affecting millions worldwide, particularly those over the age of 65. One of the major complications faced by these patients is edema, which can lead to frequent hospitalizations and requires hospitalization for intravenous diuretics.
The SUBCUT HF II trial, a randomized controlled trial, involved 170 patients across 20 National Health Service (NHS) hospitals in the U.K. Patients were randomly assigned to either continue their inpatient treatment with intravenous furosemide or to self-administer subcutaneous furosemide using the Lasix ONYU Infusor at home. This innovative device delivers furosemide in a controlled manner, allowing patients to manage their condition more independently while avoiding the confines of hospital stays.
The primary outcome measured by this trial is the total number of days patients spent alive and out of the hospital over a 30-day period, a crucial metric that underscores the importance of treatment efficacy and quality of life for heart failure patients.
SQ Innovation's Lasix® ONYU is unique in that it combines a high-concentration formulation of furosemide delivered through a specialized device designed for subcutaneous administration. The FDA approved this novel drug-device combination in October 2025, recognizing its potential to alleviate the burden of hospital-based care for heart failure patients.
The presentation at Heart Failure 2026 will not only share the trial results but also highlight the potential impacts on patient treatment paradigms; if successful, this could shift many cases of heart failure outpatient management significantly. Following the main presentation, Jan Biegus from the Institute of Heart Diseases will discuss the implications of the findings, providing further context to the scientific community.
This major trial was co-sponsored by the University of Glasgow and the Greater Glasgow and Clyde Health Board, with backing from SQ Innovation. The study’s approach recognizes the pressing need for techniques that allow patients to receive effective treatment within their homes while minimizing healthcare resource utilization. The results may pave the way for future studies and larger trials to solidify subcutaneous diuretic therapy as a valid standard of care in managing edema associated with chronic heart failure.
As heart failure rates continue to rise globally, innovations like Lasix ONYU represent a significant step toward enhancing patient autonomy and improving overall health outcomes. The SUBCUT HF II trial serves as a beacon of hope for those grappling with the challenges of heart failure, illuminating a path toward more effective and less disruptive treatment alternatives.
With this upcoming landmark presentation at Heart Failure 2026, SQ Innovation stands at the forefront of a potential paradigm shift in heart failure treatment. The healthcare community will be eager to see whether the findings substantiate the efficacy of at-home subcutaneous therapy as a viable solution for patients requiring long-term diuretic treatment, marking an important milestone in the journey of cardiac care innovation.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.